We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




PET Imaging Shows Brain Inflammation in Schizophrenics and Migraine Sufferers

By MedImaging International staff writers
Posted on 21 Nov 2009
Print article
Image: Colored positron emission tomography (PET) brain scan of a schizophrenic male patient during a hallucination (Photo courtesy of the Wellcome Dept. of Cognitive Neurology).
Image: Colored positron emission tomography (PET) brain scan of a schizophrenic male patient during a hallucination (Photo courtesy of the Wellcome Dept. of Cognitive Neurology).
Molecular imaging has been shown to reveal inflammation in the brains of schizophrenics and migraine sufferers.

Inflammatory response of brain cells--as seen by a molecular imaging technique--could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, happen and provide insight into how to best treat them, according to two studies published in the November 2009 issue of The Journal of Nuclear Medicine (JNM).

By using positron emission tomography (PET)--a noninvasive molecular imaging technique--researchers were able to identify neuroinflammation, which is evidenced by activated microglia cells (brain cells that are responsive to injury or infection of brain tissue) in patients with schizophrenia and in animal models with migraines. Although neuroinflammation has been shown to play a key role in many neurodegenerative disorders--such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease--only limited knowledge exists about the role of neuroinflammation in schizophrenia and migraines.

The two studies in the JNM are the first to identify neuroinflammation in specific regions of the brain--a development that could be used to effectively evaluate the treatment response to anti-inflammatory drugs and become transformative for diagnosis and care.

"This study shows that molecular imaging can play an important role in better understanding the processes involving psychiatric and other neurological disorders,” said Janine Doorduin, M.Sc., a researcher from the University Medical Center Groningen (The Netherlands) and lead author of the research. Mr. Doorduin added, "Without molecular imaging, the only way to look at inflammation in the brain, as well as other molecular processes, would be to use post-mortem brains.”

Not much is known about the cause of schizophrenia, a chronic, and disabling brain disease characterized by psychotic episodes of delusions and hallucinations. Previously, evidence from postmortem studies suggested the presence of activated microglia cells in the brain. However, the findings of those studies were inconsistent. Utilizing PET imaging to noninvasively image the living brains of schizophrenic patients, researchers in The Netherlands were able to pinpoint the neuroinflammation to an exact location in the brain, called the hippocampus. Now, researchers can target the hippocampus for additional study and evaluate therapeutic treatments that could improve the quality of life for patients living with schizophrenia.

Similarly, PET imaging is also useful for identifying neuroinflammation associated with migraines. In this study, researchers in Japan were the first to noninvasively visualize neuroinflammation in an animal model of migraine using a PET technique. Neuroinflammation is believed to be a key factor in the generation of pain sensation in migraine headaches. Observations from the study suggest that an inflammatory process may be involved in the pathologic state of migraines and that PET is a useful tool for evaluating the neurogenic inflammation in vivo.

"For physicians and patients, it is important to develop an objective method for the diagnosis of migraines and monitor therapeutic efficacy,” said Yi-Long Cui, Ph.D., a researcher at the RIKEN Center for Molecular Imaging Science (Kobe, Japan), and lead author of this study. "The present study will bring about these possibilities to us since the PET probe used in the paper has already been applied to patients in other diseases.”

Related Links:
University Medical Center Groningen

RIKEN Center for Molecular Imaging Science



New
Leg Wraps
Leg Wraps
New
Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
New
Mobile X-Ray Machine
MARS 15 / 30
Ultra-Flat DR Detector
meX+1717SCC

Print article

Channels

Radiography

view channel
Image: AI can identify “mammographically-visible” types of interval cancers earlier by flagging them at the time of screening (Photo courtesy of ScreenPoint Medical)

AI Improves Early Detection of Interval Breast Cancers

Interval breast cancers, which occur between routine screenings, are easier to treat when detected earlier. Early detection can reduce the need for aggressive treatments and improve the chances of better outcomes.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.